摘要 |
A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound, e.g., ABT-263, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. |
申请人 |
ABBOTT LABORATORIES;SCHMITT, ERIC A.;TONG, PING;HEEMSTRA, KATHERINE;FISCHER, CRISTINA M.;WU, HUAILIANG;MILLER, JONATHAN MARK;LI, YANXIA;LAFOUNTAINE, JUSTIN S. |
发明人 |
SCHMITT, ERIC A.;TONG, PING;HEEMSTRA, KATHERINE;FISCHER, CRISTINA M.;WU, HUAILIANG;MILLER, JONATHAN MARK;LI, YANXIA;LAFOUNTAINE, JUSTIN S. |